Organovo Subsidiary Samsara Sciences Launches Commercial Operations
Samsara is expected to serve as a key source of primary human liver cells for Organovo’s needs in the preclinical safety and therapeutic tissues markets, allowing the Company to optimize its supply chain and operating expenses related to cell sourcing and procurement.
Samsara will offer a comprehensive selection of human hepatic stellate cells – a key cell type in the liver that plays a major role in the development of prevalent diseases such as fatty liver disease and fibrosis. In addition to receiving detailed culture and cryopreservation protocols with each lot of cells, Samsara’s customers will have access to a full portfolio of companion services including the provision of tissue sections, nucleic acids and gene expression data. Human hepatocytes will also be made available through established distribution channels. To achieve its goals, Samsara works closely with key collaborator and liver cell biology expert, Dr.
“The Samsara team shares a passion for cells and is dedicated to providing the high-quality, well-characterized cellular reagents that are required to support the future of biological research and tissue products," said Dr.
“Cell supply and quality are critical to meeting Organovo’s goal to change the shape of medical research and practice, including our desire to create a bioprinted liver patch for transplant,” said
About
Organovo designs and creates functional, three-dimensional human tissues for use in medical research and therapeutic applications. The Company develops 3D human disease models through internal development and in collaboration with pharmaceutical and academic partners.
About
Samsara is dedicated to the provision of high-quality primary human liver cells for use in pharmaceutical and academic research focused on liver health and disease. The Company’s first products, primary human hepatic stellate cells are available now at www.samsarasciences.com. Primary human hepatocytes will be distributed by a third party distributor. Samsara is a wholly-owned subsidiary of
Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause the Company's actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products and services based on its technology; the expected benefits and efficacy of the Company's products, services and technology; the market acceptance of the Company's products and services; the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies; the Company's ability to successfully complete the contracts and recognize the revenue represented by the contracts included in its previously reported total contract bookings; and Samsara’s ability to commercialize its products and Organovo’s ability to achieve the anticipated supply chain benefits. These and other factors are identified and described in more detail in the Company's filings with the SEC, including its Annual Report on Form 10-K filed with the SEC on June 9, 2015 and its Quarterly Report on Form 10-Q filed with the
Investor Contact:Steve Kunszabo Organovo Holdings, Inc. +1 (858) 224-1092 skunszabo@organovo.com Press Contact:Jessica Yingling Little Dog Communications +1 (858) 480-2411 jessica@litldog.com